Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

89Bio
San Francisco, CA
www.89bio.com

89Bio is a privately held biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders. The company's lead product candidate for the treatment of NASH is BIO89-100. Currently in Phase 1, BIO89-100 is a novel long-acting glycopegylated FGF21 analogue.

Key Contact
Name
Rohan Palekar
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
10/25/18 $60,000,000 Series A Longitude Capital
OrbiMed Israel
OrbiMed US
Pontifax
RA Capital Management


Featured Reading